Treg cell therapy to help prevent rejection after child heart transplant
Part of Heart & circulation clinical trials.
This early-phase study tests a cell treatment (Treg cells made from a child’s thymus tissue) to help prevent the body from rejecting a new heart. It may help reduce rejection risk, but it is experimental and involves added risks and follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be under 2 years old and eligible for a heart transplant
- Have no reason you cannot take immune-suppressing medicines
- Have a parent or guardian who understands the study and signs consent
- Not have DiGeorge syndrome (because thymus function is affected)
- Not have certain infections or immune conditions that block participation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether Thymoglobulin® is safe and how well it works in people getting their first heart transplant. It may help doctors fine-tune medicines used to prevent the body from rejecting the new heart.
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
This trial tests a new cell therapy using Treg cells from thymic tissue to calm an overactive immune response in severe COVID-19 and ARDS. It aims to improve breathing and reduce inflammation.
This trial tests whether adding a special type of immune cell (Treg cells) to standard therapy can help kidney transplant recipients safely take lower doses of anti-rejection medicines. It is for people who are getting a kidney from a living donor.
This study tests whether special cells from your donor, called Treg cells (a type of immune cell that calms inflammation), can help treat graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have already tried other treatments but still have GVHD symptoms.
This trial tests whether giving your own regulatory T cells (a type of immune cell) back to you can help slow or stop the immune attack on your pancreas in type 1 diabetes. It is for people aged 8 to 65 who still make some insulin.
Hear when a new Heart Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.